SG11201906468TA - Chimeric antigen receptors against axl or ror2 and methods of use thereof - Google Patents
Chimeric antigen receptors against axl or ror2 and methods of use thereofInfo
- Publication number
- SG11201906468TA SG11201906468TA SG11201906468TA SG11201906468TA SG11201906468TA SG 11201906468T A SG11201906468T A SG 11201906468TA SG 11201906468T A SG11201906468T A SG 11201906468TA SG 11201906468T A SG11201906468T A SG 11201906468TA SG 11201906468T A SG11201906468T A SG 11201906468TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ror2
- axl
- cars
- chimeric antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 abstract 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 abstract 1
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 abstract 1
- 208000006265 Renal cell carcinoma Diseases 0.000 abstract 1
- 238000013475 authorization Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Abstract
40%- 30% — ap 20%— + 0 0 10% 7 0% 50% 7 7 7 7 7 C4 CO 7 LO CD N. CO 01 CD r 0.1 M V N CO N- CO CV CV CV CV (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 111111111111 0 11011111111111 01101 01111111 111111111100 1110 110 1110 111101111 (10) International Publication Number WO 2018/136570 A9 26 July 2018 (26.07.2018) WI PO I PCT (51) International Patent Classification: CO7K 16/28 (2006.01) 9618 3 9 / 3 95 (2006.01) (21) International Application Number: PCT/US2018/014122 (22) International Filing Date: 17 January 2018 (17.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/447,898 18 January 2017 (18.01.2017) US 62/467,059 03 March 2017 (03.03.2017) US 62/530,193 08 July 2017 (08.07.2017) US (71) Applicant: Fl ONCOLOGY, INC. [US/US]; 625 N. Fla- gler Dr., Suite 625, West Palm Beach, Florida 33401 (US). (72) Inventors: FROST, Gregory Ian; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). ONUFFER, James Joseph; 625 N. Flagler Dr., Suite 625, West Palm Beach, Florida 33401 (US). (74) Agent: VACCHIANO, Emanuel J.; 8110 Woodside Lane, Burr Ridge, Illinois 60527 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: CHIMERIC ANTIGEN RECEPTORS AGAINST AXL OR ROR2 AND METHODS OF USE THEREOF FIG. 1 60%- U- U- LL LL LL LL u_ u_ LL U- U- U- U- U- U- U- U- U- U- U- U- O Axl Lentriviral Particle N (57) : The present disclosure provides chimeric antigen receptors that bind to Axl and Ror2, and conditionally active chimeric antigen receptors (CARs) that recognize Axl and Ror2. Furthermore, provided herein are nucleic acids encoding these CARs and 00 methods of making and using the CARs, including methods of treating cancer, especially cancers that express Axl and/or Ror2, such O as renal cell carcinoma. The present disclosure provides cells genetically modified to produce the CARs. C [Continued on next page] WO 2018/136570 A9 IMEDIM0110101011MEN0M011101111111111111110111110111111111111 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1)) with sequence listing part of description (Rule 5.2(a)) with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i)) (48) Date of publication of this corrected version: 04 October 2018 (04.10.2018) (15) Information about Correction: see Notice of 04 October 2018 (04.10.2018)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447898P | 2017-01-18 | 2017-01-18 | |
US201762467059P | 2017-03-03 | 2017-03-03 | |
US201762530193P | 2017-07-08 | 2017-07-08 | |
PCT/US2018/014122 WO2018136570A1 (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906468TA true SG11201906468TA (en) | 2019-08-27 |
Family
ID=61157332
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107808SA SG10202107808SA (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
SG11201906468TA SG11201906468TA (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202107808SA SG10202107808SA (en) | 2017-01-18 | 2018-01-17 | Chimeric antigen receptors against axl or ror2 and methods of use thereof |
Country Status (13)
Country | Link |
---|---|
US (1) | US20190367621A1 (en) |
EP (1) | EP3571229A1 (en) |
JP (2) | JP7280827B2 (en) |
KR (1) | KR20190130559A (en) |
CN (1) | CN110177808A (en) |
AU (1) | AU2018211081A1 (en) |
BR (1) | BR112019014615A2 (en) |
CA (1) | CA3049674A1 (en) |
IL (1) | IL267902A (en) |
MX (1) | MX2019008503A (en) |
SG (2) | SG10202107808SA (en) |
TW (1) | TW201831505A (en) |
WO (1) | WO2018136570A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
WO2020047527A2 (en) * | 2018-09-02 | 2020-03-05 | F1 Bioventures, Llc | Methods and compositions for genetically modifying lymphocytes in blood or in enriched pbmcs |
US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
SI3455261T1 (en) | 2016-05-13 | 2023-01-31 | Bioatla, Inc. | Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof |
EP3847191A4 (en) * | 2018-09-07 | 2022-06-08 | BioAtla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
CN111378039B (en) * | 2018-12-29 | 2021-08-24 | 深圳大学 | Antibody for treating malignant tumor and application thereof |
CN111378040B (en) * | 2018-12-29 | 2021-08-10 | 深圳大学 | Antibody for detecting multiple malignant tumor cells and application thereof |
WO2020143506A1 (en) * | 2019-01-08 | 2020-07-16 | 深圳大学 | Detection of malignant tumor cells antibodies and uses thereof |
EP3715368A1 (en) | 2019-03-28 | 2020-09-30 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors, vectors coding for such receptors and their use in the modification of t cells |
US20230242589A1 (en) * | 2019-04-26 | 2023-08-03 | The University Of North Carolina At Chapel Hill | Chimeric antigen receptor constructs and their use in car-t cells |
CN110317277A (en) * | 2019-07-10 | 2019-10-11 | 杭州普科亭生物医药有限公司 | Chimeric antigen receptor and its application |
CN112500492B (en) * | 2019-09-13 | 2023-08-04 | 中国科学院分子细胞科学卓越创新中心 | Chimeric antigen receptor and application thereof |
US20230111159A1 (en) * | 2020-03-05 | 2023-04-13 | Exuma Biotech Corp | Methods and compositions for the delivery of modified lymphocyte aggregates |
CN114075548B (en) * | 2020-08-13 | 2023-11-21 | 广州医科大学附属第二医院 | AXL-targeted CAR-T cell, and preparation method and application thereof |
CN115125272B (en) * | 2021-03-29 | 2024-04-19 | 复旦大学 | CAR-T therapeutic vector and construction method and application thereof |
CN116102658A (en) * | 2021-11-09 | 2023-05-12 | 四川大学华西医院 | Preparation and application of chimeric antigen receptor immune cells constructed based on GAS6 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
TW197439B (en) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
JP3534749B2 (en) | 1991-08-20 | 2004-06-07 | アメリカ合衆国 | Adenovirus-mediated gene transfer into the gastrointestinal tract |
US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
FR2696458B1 (en) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Process for the preparation of taxane derivatives. |
FR2696462B1 (en) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for obtaining 10-deacetyl baccatin III. |
FR2696463B1 (en) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Process for obtaining 10-deacetyl baccatin III. |
FR2696461B1 (en) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | New derivatives of taxol analogs, their preparation and compositions containing them. |
FR2696464B1 (en) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | New esterification process for baccatin III and 10-deacetyl baccatin III. |
AU680459B2 (en) | 1992-12-03 | 1997-07-31 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
ES2249761T3 (en) | 1993-06-24 | 2006-04-01 | Advec Inc. | ADENOVIRUS VECTORS FOR GENE THERAPY. |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
DK0797676T3 (en) | 1993-10-25 | 2006-04-18 | Canji Inc | Recombinant adenoviral vector and methods for its use |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
NZ296581A (en) | 1994-12-09 | 2000-02-28 | Imp College Innovations Ltd | A method of identifying genes identified in a microorganisms ability to adapt to changes in its environment |
AU3740997A (en) | 1996-08-26 | 1998-03-19 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
AU739028B2 (en) | 1996-09-27 | 2001-10-04 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
ATE219363T1 (en) | 1997-06-20 | 2002-07-15 | Baker Norton Pharma | SOLUBLE PRODRUGS OF PACLITAXEL |
US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
JPH1192468A (en) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | New taxane derivative |
AU741433B2 (en) | 1997-10-08 | 2001-11-29 | Bio Research Corporation Of Yokohama | Taxoid derivatives and process for producing the same |
GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
EP1382969A1 (en) | 2002-07-17 | 2004-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Diagnosis and prevention of cancer cell invasion |
JP5769969B2 (en) | 2007-11-12 | 2015-08-26 | ユー3・ファーマ・ゲーエムベーハー | AXL antibody |
BRPI0820543A2 (en) | 2007-11-15 | 2015-06-16 | Chugai Pharmaceutical Co Ltd | Monoclonal antibody capable of binding to annexelekto, and use of it |
EP2406399B1 (en) | 2009-03-09 | 2018-02-14 | Bioatla, LLC | Mirac proteins |
TW201106972A (en) | 2009-07-27 | 2011-03-01 | Genentech Inc | Combination treatments |
SI2496698T1 (en) | 2009-11-03 | 2019-07-31 | City Of Hope | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION |
RU2577986C2 (en) | 2010-06-18 | 2016-03-20 | Дженентек, Инк. | Antibodies against axl and their application |
CN103747803B (en) | 2011-06-22 | 2016-10-12 | 国家医疗保健研究所 | Anti-AXL antibodies and application thereof |
US20140322234A1 (en) | 2012-01-03 | 2014-10-30 | The Board Of Trustees Of The Leland Stanford Junior University | Analysis and Targeting of ROR2 in Cancer |
US11111288B2 (en) * | 2014-08-28 | 2021-09-07 | Bioatla, Inc. | Conditionally active chimeric antigen receptors for modified t-cells |
AU2015308818B2 (en) | 2014-08-28 | 2021-02-25 | Bioatla Llc | Conditionally active chimeric antigen receptors for modified T-cells |
WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
ES2690420T3 (en) * | 2015-05-28 | 2018-11-20 | Universität Zu Köln | Anti-cough chimeric antigen receptor and its use |
CA3021086C (en) * | 2016-04-15 | 2023-10-17 | Bioatla, Llc | Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof |
AU2017320874B2 (en) * | 2016-08-31 | 2024-03-07 | Bioatla, Llc | Conditionally active polypeptides and methods of generating them |
-
2018
- 2018-01-17 BR BR112019014615-6A patent/BR112019014615A2/en unknown
- 2018-01-17 MX MX2019008503A patent/MX2019008503A/en unknown
- 2018-01-17 JP JP2019538535A patent/JP7280827B2/en active Active
- 2018-01-17 KR KR1020197024098A patent/KR20190130559A/en not_active Application Discontinuation
- 2018-01-17 US US16/478,360 patent/US20190367621A1/en active Pending
- 2018-01-17 CA CA3049674A patent/CA3049674A1/en active Pending
- 2018-01-17 WO PCT/US2018/014122 patent/WO2018136570A1/en unknown
- 2018-01-17 SG SG10202107808SA patent/SG10202107808SA/en unknown
- 2018-01-17 SG SG11201906468TA patent/SG11201906468TA/en unknown
- 2018-01-17 AU AU2018211081A patent/AU2018211081A1/en active Pending
- 2018-01-17 EP EP18703143.0A patent/EP3571229A1/en active Pending
- 2018-01-17 CN CN201880007323.XA patent/CN110177808A/en active Pending
- 2018-01-18 TW TW107101870A patent/TW201831505A/en unknown
-
2019
- 2019-07-07 IL IL267902A patent/IL267902A/en unknown
-
2023
- 2023-01-13 JP JP2023004031A patent/JP2023052397A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP7280827B2 (en) | 2023-05-24 |
CN110177808A (en) | 2019-08-27 |
BR112019014615A2 (en) | 2020-06-02 |
AU2018211081A1 (en) | 2019-07-18 |
SG10202107808SA (en) | 2021-08-30 |
TW201831505A (en) | 2018-09-01 |
JP2023052397A (en) | 2023-04-11 |
MX2019008503A (en) | 2019-09-13 |
US20190367621A1 (en) | 2019-12-05 |
WO2018136570A1 (en) | 2018-07-26 |
KR20190130559A (en) | 2019-11-22 |
CA3049674A1 (en) | 2018-07-26 |
IL267902A (en) | 2019-09-26 |
JP2020503885A (en) | 2020-02-06 |
EP3571229A1 (en) | 2019-11-27 |
WO2018136570A9 (en) | 2018-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906468TA (en) | Chimeric antigen receptors against axl or ror2 and methods of use thereof | |
SG11201909395TA (en) | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
SG11201909160WA (en) | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same | |
SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
SG11201900468YA (en) | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201907814SA (en) | Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof | |
SG11201909541WA (en) | Chimeric antibody/t-cell receptor constructs and uses thereof | |
SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
SG11201809089QA (en) | Bispecific binding proteins and uses thereof | |
SG11201908131RA (en) | Benzazepine compounds, conjugates, and uses thereof | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201900201YA (en) | Methods for quantitating individual antibodies from a mixture | |
SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201407564TA (en) | St2 antigen binding proteins | |
SG11201909728XA (en) | Constructs specifically recognizing glypican 3 and uses thereof | |
SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer |